Development of consensus recommendations

Factors contributing to teriflunomide recommendation

   Level of disease activity

   Pregnancy status

   Cost-effectiveness of a drug

   Established tolerability and safety profile

   Monitoring burden

   COVID-19 status

   Patient preference

Established tolerability and safety profile

Expert consensus and recommendations for teriflunomide usage

COVID-19: Coronavirus disease 2019; GCC: Gulf Council Countries; MS: Multiple sclerosis; RRMS: Relapsing-remitting multiple sclerosis. this study has not been reviewed by SFDA